In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytyc and Digene Strike a Deal

Executive Summary

Both Cytyc and Digene have hurdles to overcome. Skeptics fear that Cytyc, which has FDA approval for its monolayer sampling technology for cervical cancer screening, may never be more than a one-product company. And Digene, lacking sufficient sales and marketing presence in clinicians' offices, is progressing slower than many had hoped it would; it still has to clearly define the role of HPV (human papilloma virus) in cervical cancer detection and its utility as a broad screen versus what experts call "a triage tool." By entering into an exclusive agreement, the companies hope to address these issues.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts